For our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh of Revive Therapeutics (CSE: RVV), and founder of Psilocin Pharma Corp, a subsidiary of the company. Derek joins us to discuss his outlook on that of the psychedelics market as a whole, and discuss what Revive is working on from a psychedelics standpoint.
Psilocin Pharma, which was acquired by Revive Therapeutics earlier this year, is the psychedelic-focused arm of the company. The company has developed production solutions for the active compound psilocybin. The firm has developed six formulations to date, while owning a robust pipeline of ongoing research and development work within the psychedelics space.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.